- Home
- EDIT vs DFDV Comparison
EDIT vs DFDV Comparison
Compare EDIT & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | DFDV |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.8M | 219.8M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | DFDV |
|---|---|---|
| Price | $2.15 | $7.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.50 | ★ $45.00 |
| AVG Volume (30 Days) | 1.8M | ★ 2.0M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.13 |
| Revenue | ★ $46,383,000.00 | $7,526,660.00 |
| Revenue This Year | N/A | $343.83 |
| Revenue Next Year | N/A | $104.68 |
| P/E Ratio | ★ N/A | $1.60 |
| Revenue Growth | N/A | ★ 313.28 |
| 52 Week Low | $0.91 | $0.53 |
| 52 Week High | $4.54 | $53.88 |
Technical Indicators
Market Signals| Indicator | EDIT | DFDV |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 59.39 |
| Support Level | $1.95 | $4.92 |
| Resistance Level | $2.61 | $5.87 |
| Average True Range (ATR) | 0.13 | 0.59 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 28.03 | 99.23 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About DFDV DeFi Development Corp.
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.